Literature DB >> 8400973

Obesity as a determinant for response to antihypertensive treatment.

R E Schmieder1, C Gatzka, H Schächinger, H Schobel, H Rüddel.   

Abstract

OBJECTIVE: To test the hypothesis that beta blockers lower blood pressure more effectively than calcium entry blockers in obese hypertensive patients and that calcium entry blockers are more effective in lean patients.
DESIGN: Double blind, randomised controlled trial of treatment over six weeks.
SETTING: Tertiary referral centre.
SUBJECTS: 42 white men with uncomplicated mild to moderate essential hypertension (World Health Organisation stage I or II); 36 completed the study. INTERVENTION: Patients were randomised to metoprolol 50-100 mg twice daily or isradipine 2.5-5.0 mg twice daily for six weeks after a two week run in phase. MAIN OUTCOME MEASURE: Blood pressure after six weeks of treatment.
RESULTS: When stratified according to treatment and presence of obesity (body mass index < or = 27 kg/m2), the mean (SD) fall in blood pressure in the beta blocker group was 24 (13)/18 (10) mm Hg in obese patients and 18 (19)/12 (13) mm Hg in lean patients. In the calcium entry blocker group, the fall in blood pressure was 21 (15)/17 (6) mm Hg in lean patients and 18 (11)/8 (10) mm Hg in obese patients. After taking age and blood pressure before treatment into account there was a significant interaction between obesity and drug therapy (p = 0.019) with a better diastolic blood pressure response to calcium entry blockers in lean patients and to beta blockers in obese hypertensive patients.
CONCLUSION: Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400973      PMCID: PMC1678609          DOI: 10.1136/bmj.307.6903.537

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  13 in total

Review 1.  Calcium entry blockers in the treatment of hypertension. Current status and future prospects.

Authors:  N M Kaplan
Journal:  JAMA       Date:  1989-08-11       Impact factor: 56.272

2.  Volume (weight) loss and blood pressure response following thiazide diuretics.

Authors:  E D Freis; D J Reda; B J Materson
Journal:  Hypertension       Date:  1988-09       Impact factor: 10.190

3.  Cardiopathy of obesity--a not-so-Victorian disease.

Authors:  F H Messerli
Journal:  N Engl J Med       Date:  1986-02-06       Impact factor: 91.245

Review 4.  Antihypertensive treatment according to age, plasma renin and race.

Authors:  F R Bühler
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

5.  Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects.

Authors:  M L Tuck; J R Sowers; L Dornfeld; L Whitfield; M Maxwell
Journal:  Acta Endocrinol (Copenh)       Date:  1983-02

Review 6.  Physiological aspects of primary hypertension.

Authors:  B Folkow
Journal:  Physiol Rev       Date:  1982-04       Impact factor: 37.312

7.  Role of the sympathetic nervous system in blood pressure maintenance in obesity.

Authors:  J R Sowers; L A Whitfield; R A Catania; N Stern; M L Tuck; L Dornfeld; M Maxwell
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

8.  Plasma renin activity and norepinephrine as predictors for antihypertensive effects of nifedipine and captopril.

Authors:  M Kusaka; K Atarashi; K Matsumoto; Y Sumida; H Matsuura; T Shingu; G Kajiyama
Journal:  Am J Hypertens       Date:  1991-09       Impact factor: 2.689

9.  Dimorphic cardiac adaptation to obesity and arterial hypertension.

Authors:  F H Messerli; K Sundgaard-Riise; E D Reisin; G R Dreslinski; H O Ventura; W Oigman; E D Frohlich; F G Dunn
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

10.  Disparate cardiovascular effects of obesity and arterial hypertension.

Authors:  F H Messerli; K Sundgaard-Riise; E Reisin; G Dreslinski; F G Dunn; E Frohlich
Journal:  Am J Med       Date:  1983-05       Impact factor: 4.965

View more
  13 in total

1.  Managing weighty issues on lean evidence: the challenges of bariatric medicine.

Authors:  Arya M Sharma
Journal:  CMAJ       Date:  2005-01-04       Impact factor: 8.262

Review 2.  The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension.

Authors:  Revathy Carnagarin; Cynthia Gregory; Omar Azzam; Graham S Hillis; Carl Schultz; Gerald F Watts; Damon Bell; Vance Matthews; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-10-28       Impact factor: 5.369

3.  Antihypertensive treatment in patients with class 3 obesity.

Authors:  Jens Jordan; Sam W Boye; Stephanie Le Breton; Deborah L Keefe; Stefan Engeli; Margaret Forney Prescott
Journal:  Ther Adv Endocrinol Metab       Date:  2012-06       Impact factor: 3.565

4.  Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.

Authors:  Sergey V Nedogoda; Alla A Ledyaeva; Elena V Chumachok; Vera V Tsoma; Galina Mazina; Alla S Salasyuk; Irina N Barykina
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

Review 5.  Obesity, hypertension, and sympathetic nervous system activity.

Authors:  D B Corry; M L Tuck
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 6.  Management of arterial hypertension in obese patients.

Authors:  Ulrich O Wenzel; Christian Krebs
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 7.  Optimizing blood pressure control in the obese patient.

Authors:  Tobias Pischon; Arya M Sharma
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

8.  Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial.

Authors:  Sébastien Czernichow; Toshiharu Ninomiya; Rachel Huxley; André-Pascal Kengne; G David Batty; Diederick E Grobbee; Mark Woodward; Bruce Neal; John Chalmers
Journal:  Hypertension       Date:  2010-03-08       Impact factor: 10.190

9.  Nebivolol in obese and non-obese hypertensive patients.

Authors:  Camila Manrique; Adam Whaley-Connell; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-06       Impact factor: 3.738

10.  Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial.

Authors:  Barry J Materson; David W Williams; Domenic J Reda; William C Cushman
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.